Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 2 days ago

Eloxx Pharmaceuticals, Inc.: Coastlands Capital LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 14 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Coastlands Capital LP amended its Schedule 13G filing on Eloxx Pharmaceuticals, Inc., updating its beneficial ownership stake in the biopharmaceutical company under SEC accession 0001104659-26-127416. The filing, submitted to the U.S. Securities and Exchange Commission, revises the investment firm's previously reported position in Eloxx shares. Schedule 13G amendments are typically filed by passive investors whose ownership crosses or adjusts relative to the 5% threshold that triggers disclosure requirements. The update signals a change in Coastlands' holdings, though the amended filing's specific share count and percentage were not detailed in the headline disclosure. Investors will watch for further 13G or 13D filings to gauge whether Coastlands' position continues to shift and whether other institutional holders adjust their stakes in the micro-cap biotech.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Eloxx Pharmaceuticals, Inc., Coastlands Capital LP